Overview
Portfolio
More
Dynamk
New York, United States
Focus on life sciences startups, partnering with pharma and biotech to accelerate technologies for vaccines, cell and gene therapies, biologics, and therapeutics.
Portfolio
12+
Employees
5+
Founded
2017
AUM
≈ $65.0M
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
United States
Fund details
Funds
Dynamk Capital Life Sciences Fund
Dynamk Life Sciences Fund
Vintage 2021 • $65.0M
Sources
Dynamk
Focus on life sciences startups, partnering with pharma and biotech to accelerate technologies for vaccines, cell and gene therapies, biologics, and therapeutics.
Portfolio
12+
Employees
5+
Founded
2017
AUM
≈ $65.0M
Funds
Dynamk Capital Life Sciences Fund
Dynamk Life Sciences Fund · Vintage 2021 • $65.0M
Stages
No stages listed
Industries
No industries listedGeographic scope
United States
Sources
Showing 8 of 8 matched portfolio companies
Alpenglow Biosciences provides a 3D pathology platform that utilizes Hybrid Open Top Light Sheet (HOTLS) microscopy and AI analysis to deliver high-resolution imaging of biological samples. This technology enables researchers to visualize complex tissue structures and cellular distributions, enhancing drug development and clinical diagnostics by revealing insights that traditional 2D histology methods cannot capture.
Funding: $6.8M
Rough estimate of the amount of funding raised
National Institute of Health
National Institute of Health
Funding: $6.8M
Rough estimate of the amount of funding raised
The startup develops analytical testing devices that utilize combination light obscuration technology for sub-visible particle testing, which is essential for ensuring patient safety in parenteral preparations. Their services support stability testing, drug formulation, and in-process control during manufacturing, enabling clients to meet regulatory requirements and enhance product quality.
3+
1K+Approximate amount of employees
Funding: $3.9M
Rough estimate of the amount of funding raised
Dynamk Capital
Dynamk Capital
Funding: $3.9M
Rough estimate of the amount of funding raised
Bit.bio develops a cell coding platform that utilizes deterministic programming to create and manufacture any human cell type with precision and scalability. This technology addresses the need for consistent and reliable cell production for research and therapeutic applications, enabling the development of next-generation treatments.
Funding: $214.2M
Rough estimate of the amount of funding raised
Funding: $214.2M
Rough estimate of the amount of funding raised
CellFE develops a microfluidics-based device that delivers gene-editing molecules to enhance cell health and yield during the manufacturing of cell therapies. This technology addresses the challenges of long production times and high costs, enabling scalable and efficient processes from research to commercial applications.
Funding: $37.8M
Rough estimate of the amount of funding raised
Funding: $37.8M
Rough estimate of the amount of funding raised
Curi Bio develops biosystem platforms that integrate human cells and data to create 3D tissue models for drug discovery and disease modeling. Their technology enables accurate testing of drug safety and efficacy, addressing the challenges of predictive accuracy in preclinical drug development.
Funding: $10.1M
Rough estimate of the amount of funding raised
National Institutes of Health
National Institutes of Health
Funding: $10.1M
Rough estimate of the amount of funding raised
Resipher is a real-time, non-invasive oxygen consumption rate (OCR) monitoring system that utilizes patented miniature ultra-sensitive oxygen probes to continuously measure mitochondrial respiration in standard 96-well plates. This technology provides researchers with critical insights into cellular metabolism, enabling long-term tracking of metabolic activity without disturbing the cell culture environment.
Funding: $7.0M
Rough estimate of the amount of funding raised
IAG Capital Partners
IAG Capital Partners
Funding: $7.0M
Rough estimate of the amount of funding raised
Vernal Biosciences provides an end‑to‑end CDMO platform for mRNA and lipid nanoparticle (LNP) production, covering sequence design, custom synthesis, GMP manufacturing, formulation, and analytical services. Their data‑driven Quality‑by‑Design system delivers high‑purity, high‑yield mRNA material—both catalog and custom—scaled from research‑grade to clinical‑grade batches, enabling biotech and pharma companies to accelerate preclinical and clinical development.
Funding: $20.0M
Rough estimate of the amount of funding raised
+ 2 Other investorsAmpersand Capital PartnersCharles River Laboratories International
+ 2 Other investorsAmpersand Capital PartnersCharles River Laboratories International
Funding: $20.0M
Rough estimate of the amount of funding raised
Virica Biotech develops Viral Sensitizers (VSE™), patented small molecules that transiently attenuate innate cellular antiviral defenses to enhance viral vector production in gene therapy and vaccine applications. By improving yields and scalability across over 50 evaluated applications, VSEs enable more efficient manufacturing processes for critical viral products.
Funding: $9.5M
Rough estimate of the amount of funding raised
National Research Council Canada
National Research Council Canada
Funding: $9.5M
Rough estimate of the amount of funding raised
Showing 4 of 4 unmatched portfolio companies